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Summary Mycoplasma genitalium is considered the smallest 
self-replicating cell. It was first isolated in 1981, from 2 of 13 men 
with urethritis. Mycoplasma genitalium causes urethritis, cervici-
tis and pelvic inflammatory disease. Because of difficulties in cul-
tivation, the diagnosis is based exclusively on PCR methodology. 
The recommended therapy for Mycoplasma genitalium infec-
tions is azithromycin or doxycycline. Development of macrolide 
resistance was shown to correlate with treatment failure.
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IntroDuCtIon
Mycoplasma genitalium (M.) genitalium was first 
isolated in 1981, after prolonged incubation from 2 of 
13 men with urethritis (1). This fastidious organism is 
extremely difficult to isolate from clinical specimens 
with conventional culture technique; its diagnosis re-
quires the use of sensitive nucleic acid amplification 
tests (NAATs). Commercial kits are becoming avail-
able for the detection of M. genitalium; however, to 
date none of the kits has obtained the United States 
Food and Drug Administration (US FDA) approval cer-
tificate (2). The exact mode of infection and pattern 
of diseases caused by M. genitalium still remains to be 
solved, but the pathogen is presumed to be sexually 
transmitted, and infections often appear to be chron-
ic and asymptomatic (3-5). Most investigations have 
been concentrated on male urethritis patients, but M. 
genitalium has also been implicated in pelvic inflam-
matory disease, pneumonia, arthritis, and acquired 
immunodeficiency syndrome (AIDS) (6-8).
ClaSSIfICatIon anD general  
CharaCterIStICS 
M. genitalium belongs, along with other myco-
plasmas and ureaplasmas, to the family Mycoplas-
matacae, class Mollicutes. They are widely distributed 
in humans, mammals, birds, reptiles, fish, and other 
vertebrates, as well as in plants. They differ from other 
bacteria in that they lack a rigid cell wall (9,10). The 
mycoplasmas are the smallest prokaryotes capable 
of self-replication. Genital mycoplasmas represent a 
complex and unique group of microorganisms that 
have been associated with a wide array of infectious 
diseases in adults and infants. 
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The family Mycoplasmatacae contains two gen-
era: Mycoplasma and Ureaplasma. The genus Myco-
plasma contains over 100 species that inhabit a wide 
variety of plants and animals. From all these species, 
just 16 species affect genital and respiratory tract in 
humans; out of them, clinically significant are just few 
mycoplasmas: M. pneumoniae that causes atypical 
pneumonia and genital mycoplasmas M. hominis, M. 
genitalium and Ureaplasma (U.) urealyticum that have 
been associated with a wide array of infectious dis-
eases in adults and infants.
These organisms are much smaller than most 
other bacteria; hence, they are able to pass through 
bacteriologic filters. M. genitalium is the smallest 
one among the mycoplasmas with the cell diameter 
of only 300 nm and a genome size of only 580 kbp 
(9,10). 
The lack of a typical bacterial cell wall containing 
peptidoglycan renders these organisms insensitive to 
cell wall-active antimicrobial agents, such as penicil-
lins and cephalosporins. Because of this, the recovery 
of these organisms from clinical specimens may have 
significant therapeutic implications.
PathogeneSIS
The potential virulence factors in human myco-
plasmas have not been studied extensively, but some 
have been described. M. pneumoniae has been the 
widely most studied human mycoplasma; because of 
its close genetic relationship with M. genitalium, some 
features can probably be generalized. Both microor-
ganisms are primarily considered surface parasites of 
mucous membranes and possess polar tip organelles 
for attachment to host cells like adhesins (11).
The exact molecular pathogenesis of M. genitali-
um is vague, but it has been suggested that tissue 
damage is just partially caused by mycoplasma toxins 
and harmful metabolites such as hydrogen peroxide 
and superoxide.
Mycoplasmas can interact with many components 
of the immune system, inducing macrophage activa-
tion and cytokine production. Some cell components 
may act as superantigens, and could induce several 
autoimmune manifestations. M. genitalium may in-
vade epithelial cells, which may offer protection from 
antibiotics (11).
ClInICal SIgnIfICanCe of Mycoplas-
Ma genitaliuM
Genital mycoplasmas are suspected of contribut-
ing to a number of pathologic conditions. They are 
associated with various infections of the genitouri-
nary tract, reproductive failure, and neonatal morbid-
ity and mortality.
The lack of conclusive knowledge regarding the 
pathogenic potential of M. hominis and Ureaplasma 
spp. in many conditions is due to their high frequency 
in healthy persons and the poor design of research 
studies. Besides, isolation of M. genitalium is very dif-
ficult. The situation is now changing because of in-
troducing molecular methods in detection of genital 
mycoplasmas. 
Nongonococcal urethritis (NGU) is a common 
condition in men. Men with NGU can be categorized 
into those with and without Chlamydia (C.) trachoma-
tis infection (12,13). In the studies performed in the 
early 1990s, it has been reported that C. trachomatis 
was the cause of 35%-50% of NGU cases (14). More 
recently, it was observed that C. trachomatis caused 
approximately one-third of NGU cases (15). So, in the 
majority of cases, the clinical syndrome is referred to 
as nonchlamydial nongonococcal urethritis (NCNGU). 
However, in a significant percentage of urethritis 
cases, the causative agent could not be found (16). 
In 1981, M. genitalium was first isolated from the ure-
thras of 2 of 13 men with urethritis (1). Studies that 
attempted to assess its association with disease were 
hampered by the difficulty of growing the organism 
in culture (1). In more recent years, more reliable de-
tection has become possible after the development 
of specific polymerase chain reaction (PCR) assays. 
In the 1990s, large numbers of papers on the role 
of M. genitalium in male non-gonococcal urethritis 
were published. Although different criteria were used 
to define patient and control groups, all the studies 
demonstrated a higher prevalence of M. genitalium 
in the groups of patients with NGU (17,18). In those 
studies from different countries, the prevalence of 
M. genitalium in patients with NGU ranged from 13% 
to 42%, and in asymptomatic men from 0% to 15% 
(19). In Croatia, the prevalence in symptomatic men is 
2.3% (unpublished data, Plečko, Žele).
Moreover, M. genitalium appears to be detected 
with highest prevalence in men with C. trachomatis 
negative urethritis. Several studies have shown that 
men with M. genitalium positive NGU have symptoms 
at least as often as those with chlamydial urethritis. 
Systematic studies linking M. genitalium to the com-
plications such as epididymitis and prostatitis are 
lacking. However, M. genitalium DNA has been found 
both in the urethra of men with epididymitis, and in 
the prostatic tissue of men with prostatitis (20,21). 
Detection of M. genitalium in men with acute NGU 
also was associated significantly with balanitis and/or 
posthitis (22). 
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Like U. urealyticum and M. hominis, M. genitalium 
attaches to spermatozoa, but there is no evidence of 
its role in sperm quality (21). 
In women, the presence of M. genitalium is associ-
ated with cervicitis and urethritis. M. genitalium can be 
detected in the endometrium of women with pelvic 
inflammatory disease, and, on a single occasion, was 
found in the fallopian tube (23-25). It has also been 
confirmed that M. genitalium is associated with pelvic 
inflammatory disease, independently of gonococ-
cal or chlamydial infection. Several PCR-based stud-
ies from geographically diverse populations confirm 
that M. genitalium is associated with clinical pelvic in-
flammatory disease. In these infections, M. genitalium 
is diagnosed in 13%-16% of cases. Serologic studies 
suggest a strong association between past infection 
with M. genitalium and tubal factor infertility (26).
DIagnoSIS
Genital mycoplasmas (M. hominis and U. urea-
lyticum) can be cultivated in the enriched broth that 
contains arginine, urea and phenol red indicator. This 
broth is inoculated with the specimen and is incu-
bated aerobically at 35 °C. The medium is observed 
for changes in the color of the indicator. Namely, the 
growth of the mycoplasmas changes pH; subculture 
to solid media and subsequent incubation allows for 
recovery and identification of both M. hominis and U. 
urealyticum. The culture of M. genitalium is extremely 
difficult, time-consuming and lasts up to 8 weeks. 
This is the reason why cultivation of M. genitalium is 
used for research purposes only (11).
From the early 1990s, detection of M. genitalium is 
dependent mainly on PCR methods (1). These assays 
were based on the MgPa gene (encoding the major 
surface protein MgPa) and 16S rRNA gene sequence 
(11). First assays were based on the MgPa DNA se-
quence, but in further studies genetic variability of 
the MgPa gene was observed, so there was a risk of 
false negative reactions using these primers. Later, 
the MgPa-1/MgPa-3 assay was validated as a confir-
matory assay as part of the development of 16S rRNA 
gene PCR. Briefly, 16S rRNA positive result is further 
confirmed by MgPa-1/MgPa-3 PCR (11). 
The first real-time PCR assay for M. genitalium was 
published by Jensen et al. in 2002 (27). Later, numer-
ous studies used quantitative methods (28,29). These 
assays are very sensitive and specific. The MgPa gene 
and 16S rRNA encoding-genes of M. genitalium are 
most commonly used as targets in M. genitalium qPCR. 
In a recently published study, Müller et al. have devel-
oped a quantitative real-time Rotor-Gene PCR (qPCR) 
assay targeting the pdhD gene of M. genitalium (29).
Quantitative PCR is a useful tool for detecting M. 
genitalium bacterial loads in a range of samples, in-
cluding vaginal and cervical swabs, urethral swabs, 
and first-void urine (30). Based on published litera-
ture, first-pass urine sample appears to be a better 
sample for men than urethral swab (31). Several qPCR 
assays are able to detect and quantify M. genitalium 
as low as 2 copies/reaction (29). 
The commercial assays for detection of M. genitali-
um are available, such as the AmpliSens® Mycoplasma 
genitalium, Eph PCR kit, Bio-Rad Dx CT/NG/MG as-
say, Euroclone DUPLICa kit, and Gen-Probe; how-
ever, none has yet obtained the US FDA approval. At 
present, most laboratories use kits for research, so it 
is important that laboratories actively engage in ex-
ternal quality assurance programs using real clinical 
specimens before they introduce molecular methods 
in routine (2). 
antIbIotIC theraPy
The current recommended treatment for M. geni-
talium infection is the macrolide antibiotic azithromy-
cin. A comparative trial and one observational study 
have both shown that a single 1 g dose of azithro-
mycin is significantly more effective than multi-dose 
doxycycline, with cure rates of 86%-87% versus 22%-
45% (2). Development of macrolide resistance has 
been shown to correlate with subsequent azithro-
mycin treatment failure. The genetic basis for drug 
resistance was shown to be mutations in region V of 
the 23S rRNA gene, which is well described in other 
Mollicutes. The genetic basis for drug resistance was 
established by sequencing parts of the 23S ribosom-
al RNA gene and the genes encoding the L4 and L22 
proteins (31-33). These findings raise concern about 
the use of single-dose azithromycin treatment of 
nongonococcal urethritis of unknown etiology. In 
case of persistent symptoms of M. genitalium ure-
thritis or detection of macrolide resistance, the rec-
ommended therapy is moxifloxacin 400 mg daily for 
7-10 days (2).
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